id: NEW:naltrexone_treatment_availability_pregnant_to_alcohol_use_disorder
name: Naltrexone Treatment Availability for Pregnant Individuals â†’ Alcohol Use Disorder
from_node:
  node_id: NEW:naltrexone_treatment_availability_pregnant
  node_name: Naltrexone Treatment Availability for Pregnant Individuals
to_node:
  node_id: alcohol_use_disorder
  node_name: Alcohol Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Limited availability of naltrexone prescribers willing to treat pregnant patients (only 35.9%
  of responding sites)'
- 'Step 2: Geographic variation creates treatment deserts, particularly outside the Northeast US'
- 'Step 3: Pregnant individuals with AUD face barriers to accessing evidence-based pharmacotherapy'
- 'Step 4: Untreated or undertreated AUD during pregnancy leads to worse maternal and fetal outcomes'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Chloe Deflorimonte et al. 2023. "National Provider Survey: Use of Naltrexone for
    Pregnant Individuals with Substance Use Disorders." https://doi.org/10.1097/ADM.0000000000001225'
  supporting_citations:
  - Additional citations require full-text access - abstract references national registry of naltrexone
    prescribers (N=5208)
  - Additional citations require full-text access - references to national guidelines mentioned as barrier
  - Additional citations require full-text access - safety concern literature referenced
  doi: 10.1097/ADM.0000000000001225
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: This survey of naltrexone prescribers found that only 35.9% of sites offered naltrexone for
  pregnant individuals with alcohol use disorder or opioid use disorder. Major barriers included absence
  of pregnant patients at sites (15.6%), lack of national guidelines (14.1%), provider safety concerns
  (9.4%), and provider inexperience (4.7%).
quantitative_effects:
  effect_size:
    value: 35.9
    type: percentage_change
  sample_size: 78
spatial_variation:
  varies_by_geography: true
  variation_notes: Significant geographic variation identified with Northeast United States having the
    most available sites; other regions have fewer options for pregnant individuals seeking naltrexone
    treatment
moderators:
- name: lack_of_national_guidelines
  direction: weakens
  strength: moderate
  description: 14.1% of providers cited lack of national guidelines as a barrier to prescribing naltrexone
    for pregnant patients
- name: provider_safety_concerns
  direction: weakens
  strength: moderate
  description: 9.4% of providers reported discomfort prescribing due to safety concerns during pregnancy
- name: provider_inexperience
  direction: weakens
  strength: weak
  description: 4.7% of providers reported discomfort due to inexperience treating pregnant patients
structural_competency:
  equity_implications: 'This mechanism highlights structural healthcare access barriers rather than individual
    patient factors. The limited availability of naltrexone treatment for pregnant individuals reflects
    systemic gaps including: 1) lack of policy guidance through national treatment guidelines, 2) inadequate
    provider training and education on pregnancy-specific treatment, 3) geographic maldistribution of
    services creating treatment deserts. These structural factors disproportionately affect pregnant individuals
    in regions outside the Northeast, creating geographic inequities in access to evidence-based SUD treatment.
    The absence of comprehensive guidelines leaves individual providers to make decisions without institutional
    support, perpetuating treatment gaps.'
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.208448'
  extraction_confidence: medium
  prompt_version: 2.1-canonical-validated
